Lisata Therapeutics shares surge 19.31% after-hours on positive preclinical data showing certepetide enhances ADC efficacy and tumor penetration.

Lisata Therapeutics surged 19.31% in after-hours trading following the announcement of positive preclinical data from its licensing partner, Catalent, at the 16th Annual World ADC Conference. The data demonstrated that certepetide, Lisata’s proprietary cyclic peptide, enhanced the efficacy and tumor microenvironment distribution of Catalent’s SMARTag® ADC platform when used as a non-cytotoxic payload. The results reinforced certepetide’s potential to improve ADC targeting and penetration, aligning with Lisata’s strategy to leverage its CendR Platform® for advanced solid tumor treatments. The partnership’s progress, coupled with certepetide’s Fast Track and Orphan Drug designations, likely drove investor optimism about the drug’s therapeutic value and commercial prospects.